The malaria drug is quickly falling out of favor with the medical community as a potential treatment for the disease. On the back of mounting concerns about hydroxychloroquine's safety, global pharmaceutical major Sanofi (NASDAQ:SNY) has quit providing it to COVID-19 patients enrolled in its clinical trials for the drug. It has also put a temporary…
A box of Plaquenil, an anti-malaria drug hydroxychloroquine made by Sanofi, used for years to treat malaria and autoimmune disorders.Alain Pitton | NurPhoto | Getty ImagesFrench drugmaker Sanofi said Friday it is suspending recruitment of new patients for its clinical trials looking at anti-malaria drug hydroxychloroquine as a potential treatment for the coronavirus.The company is also…
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed a new weight loss pill approved by the FDA on CBS News’ CBS Mornings on April 2. Click here to watch Gounder on CBS Mornings. KFF Health News Southern correspondent Sam Whitehead discussed high Affordable Care Act premiums on WUGA’s The Georgia Health Report on
States are paying contractors such as Deloitte, Accenture, and Optum millions of dollars to help them comply with the One Big Beautiful Bill Act — a law that will strip safety-net health and food benefits from millions. State governments rely on such companies to design and operate computer systems that assess whether low-income people qualify
You don't have permission to access "http://www.medpagetoday.com/hematologyoncology/prostatecancer/120620" on this server. Reference #18.2c153b17.1775163741.18014a6 https://errors.edgesuite.net/18.2c153b17.1775163741.18014a6